Less than one out of three patients will survive two years after their diagnosis of glioblastoma. We must continue to raise awareness about glioblastoma because more research and new treatment options can make a difference in this deadly disease.
Today’s approved front-line chemotherapies to treat glioblastoma work through the same mechanism of action that can be counteracted by an enzyme called MGMT. Our first drug in development, VAL-083, works differently to kill cancer cells and is unaffected by MGMT, making it a potential first-in-class treatment for glioblastoma multiforme (GBM).
We at DelMar are very focused on developing new therapies for patients with little to no treatment options. We are testing VAL-083 in refractory glioblastoma, where there is the greatest need and greatest potential impact, and we are running our clinical studies as quickly as possible to get this promising drug into the hands of physicians to treat the patients who need it the most.
Key Facts:
- Nearly 12,000 people are diagnosed with glioblastoma each year in the United States.
- Approximately two out of three glioblastoma patients will fail today’s approved therapies.
- Many patients develop resistance to the front-line therapy, Temodar®, because of an enzyme known as MGMT.
- VAL-083 acts through a mechanism independent of MGMT.
- Historical clinical trials and interim clinical trial results presented at AACR and ASCO suggest VAL-083 is safe and well tolerated by patients at doses tested to date.
- Studies by the National Cancer Institute and DelMar have shown VAL-083 to have activity against a range of cancers, including glioblastoma.
- New immune-based therapeutic approaches, such as cancer vaccines, gene therapies and viral therapies, such as modified polioviruses, are often combined with chemotherapy, so developing new chemotherapies, like VAL-083, is essential.
- DelMar is conducting a Phase I/II clinical trial for VAL-083 at UC San Francisco and the Sarah Cannon Research Institute in Nashville, Tennessee and Sarasota, Florida.
- VAL-083 has received orphan drug designation in Europe and the United States.
More research and new treatment options make a difference. Please share to help raise awareness for brain cancer research.
Why is glioblastoma so deadly?
What causes chemotherapy resistance?
What is VAL-083 and how can it better fight glioblastoma?
What are the new therapies in development for glioblastoma?
DelMar’s fight against cancer